# ImmuneSense™ IBD Study

> **NCT05769829** · — · TERMINATED · sponsor: **Adaptive Biotechnologies** · enrollment: 484 (actual)

## Conditions studied

- Inflammatory Bowel Diseases

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05769829
- **Lead sponsor:** Adaptive Biotechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-31
- **Primary completion:** 2023-08-14
- **Final completion:** 2023-08-14
- **Target enrollment:** 484 (ACTUAL)
- **Why stopped:** Enrollment challenges for cohort 2
- **Last updated:** 2023-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05769829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05769829, "ImmuneSense™ IBD Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05769829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*